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Hepatic porphyries have been associated with an increased risk of primary liver cancer (PLC), which on the other hand may
cause an increased porphyrin production. To evaluate the role of an underlying liver disorder we analyzed porphyrins in patients
with hepatocellular carcinoma (HCC) (n = 65), cholangiocellular carcinoma (n = 3), or suspected PLC, which turned out to
be metastases (n = 18) or a benign disorder (n = 11). None of the patients had a family history of porphyry or clinical signs
of porphyry. Increased aminolevulinic acid or porphyrin values were common not only in patients with PLC (43%) but also in
metastatic(50%)andbenign(64%)liverdisorders.ThecorrespondingproportionforHCCpatientswithlivercirrhosis(55%)was
higher (P<. 05) than in those without cirrhosis (17%). We conclude that symptomatic porphyries are unusual in PLC, whereas
elevated urinary and/or faecal porphyrins are common, primarily reﬂecting a parallel liver disease and not the PLC.
Copyright © 2009 Jerzy Kaczynski et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Primary liver cancer (PLC), and particularly its most
predominant histological type, hepatocellular carcinoma
(HCC), is one of the most common malignancies in the
world [1]. The incidence rates vary widely throughout the
world [2]. Sweden is a low-rate area where PLC accounts
for less than 2% of all diagnosed cancers [3]. Cirrhosis of
the liver plays an important role for the PLC development,
and important etiological factors for HCC are reported to be
hepatitis B and C viruses, alcohol, and diabetes [2, 4–8].
Among other causes of PLC an association with hep-
atic porphyries has been recognized, especially with acute
intermittent porphyry (AIP) [9–16] and porphyria cutanea
tarda (PCT) [15, 17–22], but also with porphyria variegata
[14, 16, 23] and hereditary coproporphyria [14, 16, 24]. A
relation between AIP and HCC was ﬁrst noted in northern
Sweden [9] and was supported in additional studies from
Scandinavia [10–13, 15, 25] and other countries [14, 16, 26,
27]. The incidence of HCC in PCT has been reported to be
from zero% to 34% [20, 21, 28–30].
The most common type of PCT is an acquired form,
which is triggered by toxic (e.g., alcohol) and infectious (e.g.,
hepatitis C virus) factors or haemosiderosis [28, 31, 32],
and liver cirrhosis and hepatic iron overload are common
associated ﬁndings [19]. Although each of these factors is
known to increase the risk of HCC as well [5, 6, 33, 34], it
has been suggested that PCT per se increases this risk further
[18, 22].
Porphyry in patients with PLC as a paraneoplastic phe-
nomenon is a well-documented but rare condition [19, 35,
36]. The reported cases had all photosensitive skin lesions,
but in several instances the pattern of porphyrin excretion
was not consistent with true PCT. Secondary AIP has also
been reported [37]. Abnormalities in porphyrin metabolism
without clinical picture resembling hepatic porphyries are
also described in patients with liver tumours and other
liver diseases [38, 39]. However, little is known about the
frequency and excretion patterns of urinary and particularly
faecal porphyrins in patients with PLC.
The aim of the present study was to determine the excre-
tion of urinary and faecal porphyrins and their precursors2 Gastroenterology Research and Practice
by conventional methods in PLC patients in order to
(i) reveal undiagnosed porphyry cases in order to elucidate
the signiﬁcance of porphyries for PLC, and (ii) examine
whether elevated urinary and/or faecal porphyrins are
associated with PLC per se, a parallel or another liver disease.
2.MaterialandMethods
2.1. Patients. This study was performed as a part of a
prospective study of patients with PLC in G¨ oteborg, Sweden.
All patients who were admitted to hospital because of a
strong suspicion of PLC and who came to the authors’
attention were included in the study, which was ethically
conducted in accordance with the principles of the 1983
Declaration of Helsinki. Since the diagnostic procedures
did not made it possible to conﬁrm or exclude PLC in
ﬁve of the 109 patients primarily included in the study,
they had to be excluded. In further 7 cases it was not
possible to determine the excretion of porphyrins and their
precursors, either because the sampling was not performed
for various reasons, such as unexpected death, or if it
was performed incorrectly or insuﬃcient, and so forth.
Of the remaining 97 cases (Table 1) the ﬁnal diagnosis
was PLC in 68 cases, malignancy other than PLC in 18
cases, and benign liver disorders in 11 cases. These latter
29 patients constituted control groups I and II in this
study.
All patients were interviewed (JK or SW) with regard to
clinical or family history of porphyries, haemochromatosis,
and chronic alcoholism. The patients were followed up by
personal examination and by study of their clinical records.
2.2. Sampling and Biochemical Analyses. Within one week
from the interview two samples of 24-hour urine and one
sample of faeces were collected from each studied subject.
One 10mL sample of 24-hour urine was alkalized with 5g
sodiumbicarbonateandanalyzedwithregardtothepresence
of porphobilinogen (PBG) with a qualitative method. The
presence of elevated concentrations of porphyrins were
analyzed in the same urine sample with a qualitative and/or
quantitative method (spectrophotometry) and expressed as
0-1 (absence-presence), in µmol/24hour and/or mmol/mol
creatinine. Aminolevulinic acid (ALA) was analyzed in
another 24-hour urine sample after acidiﬁcation with 30mL
hydrochloric acid, 5mol/L. It was determined by ion-
exchange chromatography and expressed in µmol/24hour
and/or mmol/mol creatinine. Porphyrins in faeces were
determined in a sample of about 5g, by thin-layer chro-
matography. Coproporphyrins (CPs) and protoporphyrins
(PPs)wereexpressedinnmol/gfaeces.Transferrinsaturation
in serum was also measured in every patient.
2.3. Histopathological Examinations. The specimens for
histopathological examination were obtained by biopsy ante
mortem (needle, wedge biopsy or tissue blocks of resected
tumours) or at autopsy. The formalin-ﬁxed, paraﬃn-
embedded tissue specimens were collected, and slides for
light microscopy were stained with haematoxylin and eosin.
To improve accuracy of the diagnosis, some cases were also
stained with Grimelius stain (silver) and chromogranine and
some were studied immunohistochemically by use of the
peroxidase/anti-peroxidase (PAP) method for presence of
alpha-fetoprotein, thyroglobulin, factor VIII, and prostate
speciﬁc antigen. The slides of all cases with ﬁnal diag-
nosis of HCC were also stained with Perl’s Prussian blue
stain for iron. Siderosis was graded as follows: (0) absent
(1) minimal, (2) moderate, (3) abundant, and (4) massive.
All the microscopic slides were reviewed by two of us (GH,
JK) and studied also with regard to the diagnosis and the
histology of available, nonneoplastic liver tissue.
PLC was classiﬁed according to Anthony and The
international working party [40, 41]. In eight cases without
available or insuﬃcient tissue specimens, a diagnosis of
HCC was established since they fulﬁlled at least two of the
followingthreecriteria:(1)diagnosisofHCCassaidbycyto-
logical examination of a ﬁne-needle aspiration specimen,
(2) radiological suspicion of PLC, and (3) alpha-fetoprotein
concentration in serum > 500µg/L [42].
2.4. Statistical Analyses. Standard statistical methods were
employed, using the group comparison t test for comparison
of two mean values and the chi-square or Fisher’s exact test
for comparison of two proportions.
3. Results
3.1. Patients. The mean age of the PLC patients at the time
of inclusion was 68 years with no signiﬁcant sex diﬀerences.
The male to female ratio was 3 : 1 (Table 1). The patients
with benign liver disorders were signiﬁcantly younger than
both PLC patients (P<. 01) and patients in control group I
(P<. 05). Twenty-one of the 97 patients (22%) had a history
of heavy alcohol consumption but there were no signiﬁcant
diﬀerences between the study groups.
None of the patients had a clinical or family history of
porphyry or haemochromatosis, nor did any of them exhibit
any porphyry symptoms during the followup. All patients
with PLC and metastatic liver disease died during the study
period.
3.2. Histopathology. There were 65 cases of HCC and 3 cases
of CCC. Cirrhosis of the liver could be established in 24 of
36 HCC cases (67%) in which nonneoplastic liver tissue was
available for microscopic examination. In seven additional
cases there was a strong clinical suspicion and/or typical
macroscopic appearance of cirrhosis at autopsy. In 22 HCC
cases, however, it was not possible to conﬁrm or exclude
cirrhosis clinically or histopathologically due to insuﬃcient
nonneoplastic liver tissue or autolytic changes. There was no
case of massive siderosis in the nonneoplastic liver tissue and
only four cases of moderate/abundant siderosis, all of which
had cirrhosis and HCC. Alcohol and hepatitis C were the
predominant causes of liver cirrhosis (Table 2). The cirrhosis
was unknown before HCC diagnosis in 18 cases and well
compensated in the remaining 13 patients.
In the control group I, that is, 18 patients with a
metastatic liver disease, there was one case with liver
cirrhosis.Gastroenterology Research and Practice 3
Table 1: Proportion of evaluable patients (%) with elevated urinary and/or faecal porphyrins measured as concentration of a metabolite
above the laboratory reference range (Upper limit of normal, ULN) in cases with primary liver cancer, metastatic liver disease, and benign
liver disorders. ALA : aminolevulinic acid; PBG : porphobilinogen.
Primary liver cancer Metastatic liver disease Benign liver disorders
n = 68 n = 18 n = 11
Age (years, range) 68 (49–92) 67 (39–81) 54 (27–74)
Sex (M/F) 51/17 9/9 4/7
U-ALA (% above ULN) 113 295 27
U-PBG (% above ULN) 02 05 08
U-Porhyrins (% above ULN) 151 125 139
F-Coproporhyrins (% above ULN) 204 307 509
F-Protoporphyrins (% above ULN) 354 456 338
1n = 65, 2n = 64, 3n = 61, 4n = 49, 5n = 17, 6n = 11, 7n = 10, 8n = 9, 9n = 8.
Table 2: Etiology of cirrhosis in 31 patients with HCC.
Etiology n %
alcohol1 13 42
hepatitis C
1 72 3
autoimmune hepatitis 1 3
primary biliary cirrhosis 1 3
alpha-1-antitrypsin deﬁciency 1 3
NASH 1 3
hepatitis B 0 0
unknown 9 29
1includes 2 cases with history of both alcohol abuse and hepatitis C.
In the control group II, that is, 11 patients with benign
liver diseases, there were four cases with liver cirrhosis, three
with histological normal liver or steatosis, two with liver
abscess, and one of each with peliosis hepatis and a benign
liver tumour (ﬁbrous histiocytoma).
3.3. Biochemistry. Totally, concentration values above the
laboratory reference range of at least one of ALA, urinary
porphyrins, CP, or PP in faeces, were found in 43% in
the PLC group, 50% in group I, and 64% in group II.
The diﬀerences between these groups were not signiﬁcant.
The corresponding ﬁgure for patients with HCC and liver
cirrhosis (55%) was higher (P<. 05) than for noncirrhotic
patients with HCC (17%).
ALA. There was no signiﬁcant diﬀerence in frequency of
increased concentration of ALA in urine between the groups
(Table 1). Most of these patients had only slightly increased
concentrations (reference limit < 40µmol/24h and <
3mmol/mol creatinine). The highest values (120µmol/24h
and 26mmol/mol creatinine) were found in a patient with
HCC without cirrhosis. This patient had a concentration of
porphyrins in urine and faeces within the reference range.
PBG. There was not a single case with qualitatively
detectable urinary levels of PBG.
Urinary Porphyrins. The presence of increased concentra-
tions of urinary porphyrins, measured qualitatively and/or
quantitatively, was noted more often in HCC patients with
than without liver cirrhosis (P<. 05) (Table 3). The highest
concentration of porphyrins, 1.4µmol/24hour (reference
limit < 0.6) and 0.26mol/mol creatinine (reference limit
< 0.04), was found in a patient with HCC and liver cirrhosis
related to alpha-1-antitrypsin deﬁciency.
Porphyrins in Faeces. The ﬁnding of increased concentra-
tions of CP and/or PP in faeces was common in both PLC
patients (39%) and the controls (45% and 44%, resp.). The
diﬀerences were not signiﬁcant. In HCC patients it was
more common (P<. 05) with increased concentrations of
CP and/or PP in faeces in those with underlying cirrhosis
(59%) than in noncirrhotic HCC patients (11%). The
highest value of CP, 64nmol/g faeces (reference limit <
20nmol/g), was found in a 71-year-old patient with modest
alcohol consumption and a high serum concentration of
alpha-fetoprotein (>10000µg/L). Due to autolytic changes
it was not possible to state a histopathological diagnosis.
At autopsy, however, the liver had a typical macroscopic
appearance of cirrhosis and HCC. The highest values of PP,
750 and 760nmol/g faeces (reference limit < 70nmol/g),
were found in a patient with alcoholic liver cirrhosis without
HCC and in a patient with liver cirrhosis of unknown
aetiology with HCC, respectively. The latter patient had also
the highest values of CP but values of ALA and porphyrins in
urine within the reference range.
There was no signiﬁcant diﬀerence in frequency of
increased urinary and/or faecal porphyrins between alco-
holics (43%) and other patients and (47%).
Siderosis of the Liver and Transferrin Saturation. One of the
four patients HCC with liver cirrhosis and siderosis had
increased concentrations of ALA and urinary porphyrins.
Two of these four patients and additional two had high
(>55%) transferrin saturation. They were all alcoholics.
One had increased concentrations of ALA and urinary
porphyrins (same patient as above) and one had increased
concentrations of urinary porphyrins and PP in faeces.4 Gastroenterology Research and Practice
Table 3:Frequencyofelevatedurinaryand/orfaecalporphyrinsin43patientswithhepatocellularcancer(HCC),wherepresenceofcirrhosis
could be established. In each column is given the proportion (%) of evaluable patients with concentrations above the laboratory reference
limit (Upper limit of normal, ULN). ALA : aminolevulinic acid; PBG : porphobilinogen; NS : non signiﬁcant.
HCC with cirrhosis HCC without cirrhosis Diﬀerence between groups
n = 31 n = 12
Age (years, range) 68 (49–83) 65 (51–72)
Sex (M/F) 27/4 6/6
U-ALA (% above ULN) 71 84 NS
U-PBG (% above ULN) 02 04 NS
U-Porhyrins (% above ULN) 281 04 P<. 05
F-Coproporhyrins (% above ULN) 363 95 NS
F-Protoporphyrins (% above ULN) 553 95 P<. 05
1n = 29, 2n = 28, 3n = 22, 4n = 12, 5n = 11.
4. Discussion
Our ﬁnding of a substantial number of PLC patients with
increasedconcentrationsofurinaryand/orfaecalporphyrins
should not be surprising, since porphyries are not unusual
in liver disease [28, 31, 32, 38, 39]. The characteristics of
the PLC patients in our study with regard to frequency of
cirrhosis, age, and sex are in agreement with ﬁndings in
a large comprehensive retrospective study from the same
area and should thus be regarded as representative for PLC
in Sweden [43]. It thus seemed appropriate to compare
porphyrin divergences in our PLC cases not with healthy
people but with patients suﬀering from other liver disorders,
especially patients with clinical signs suspect of PLC. Since
the frequency of elevated porphyrins, to our knowledge, has
notbeenstudiedinmetastaticliverdisease,thecontrolgroup
was divided in patients with either a benign or a malignant
(other than PLC) liver disorder.
There was not a single case of AIP or PCT in our
study, which indicates that porphyries generally play a minor
etiologic role for PLC. The ﬁnding of increased PBG in urine
in patients with PLC has been reported [44] but seems to
be rare. This is in accordance with the results in our study.
However, we cannot rule out the possible etiological role
of AIP in the development of PLC in single cases, since the
prevalence of this disease is low and only about one third of
the AIP gene carriers have increased PBG levels in the urine
[45].
An acquired form of PCT has been associated with
various liver disorders such as cirrhosis, and hepatitis C virus
infection [28, 38, 46]. The majority of PLC cases arise in
cirrhoticlivers[2]andhepatitisCvirusisonemajoretiologic
factor for HCC [5, 40]. Thus, most of the cases of PCT with
PLC seem to be the result of the same liver disorder.
None of the patients in our study developed a clinical
picture resembling hepatic porphyry. The patients with
elevated porphyrins had a pattern of ALA and porphyrin
excretion in urine and faeces, diﬀerent from that observed
in AIP and PCT. Since the prognosis for PLC is usually very
poor [47–49], the time would be too short for accumulation
of porphyrins to levels, giving clinical porphyry symptoms
[38]. In our study the median survival rate from the time of
the diagnosis was two months.
The ﬁnding of elevated urinary and/or faecal porphyrins,
withoutexhibitingclinicalsymptomsresemblingporphyries,
was common in PLC patients in our study. However, this
ﬁnding was also common in both patients with metastatic
and benign liver diseases. Since there was no characteristic
pattern of ALA and porphyrins excretion in PLC, increased
porphyrin secretion may indicate a liver disorder but not
speciﬁcally PLC.
Our results suggest that elevated urinary and faecal
porphyrins are common in many liver disorders, irrespective
of if they are malignant or not. Since the liver plays a
dominant role in haeme synthesis [50], it is not surprising
that functional morphological disturbances and malignant
degeneration may lead to disorderly haeme synthesis, not
unlike the porphyries [18, 38, 51]. The possible subsequent
clinical manifestation seems to depend on level and constel-
lation of porphyrin accumulation and excretion [38]. Thus,
in one study almost one-third of all patients with chronic
liver damage showed a pathological porphyrinuria [38].
However, porphyrinuria is often transient and reversible
[39].
Whatever the mechanism, both PLC and other liver
disorders may lead to increased ALA and/or porphyrins
synthesis, as shown in our study. This chronic porphyry
presents a variable constellation of ALA and porphyrin
excretion pattern in urine and faeces.
WeconcludethatalthoughincreasedALAandporphyrin
values in urine and/or faeces in PLC patients were found
to be frequent, this seems to cause symptomatic porphyries
only in exceptional cases. Since increased porphyrin values
were common especially in HCC patients with concomitant
cirrhosis, and also in other (malignant and benign) liver
diseases, these disturbances probably primarily reﬂect an
underlying, parallel or another liver disease and are not
characteristic for PLC per se.
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